Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 3/20 | 0.51 |
| ▸ | JAK1 | P23458 | 3/20 | 0.51 |
| ▸ | TYK2 | P29597 | 3/20 | 0.51 |
| ▸ | JAK3 | P52333 | 2/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.50 |
| ▸ | PDE4A | P27815 | 2/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491533 | 0.93 | GPR119 (0.48) | GPR119KDM1AJAK2JAK1TYK2 | |
| SCHEMBL5241503 | 0.83 | KDM1A (0.53) | GPR119KDM1APDE4BPDE4DPDE4A | |
| SCHEMBL14143336 | 0.83 | JAK1 (0.57) | GPR119JAK2JAK1TYK2JAK3 | |
| SCHEMBL5454387 | 0.82 | GPR119 (0.57) | GPR119KDM1APDE4BPDE4DPDE4A | |
| SCHEMBL3928952 | 0.81 | JAK2 (0.46) | GPR119JAK2JAK1BRD4 | |
| SCHEMBL19297086 | 0.79 | BRD4 (0.53) | GPR119KDM1AJAK2JAK1TYK2 | |
| SCHEMBL30885791 | 0.79 | GAA (0.60) | — | |
| SCHEMBL1537795 | 0.79 | GAA (0.60) | — | |
| SCHEMBL19402410 | 0.79 | KDM1A (0.58) | GPR119KDM1APDE4BPDE4DPDE4A | |
| SCHEMBL19839235 | 0.78 | PDE4B (0.64) | GPR119KDM1APDE4BPDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-12-24 | — | — | US | disclosed |
| EP-2043744-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008895-A1 | GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008887-A2 | GPR119 AGONISTS FOR TREATING METABOLIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GPR119, GOT2, SLC5A2 | GPR119 1/4885KDM1A 4302/4885JAK2 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.